Compare AbbVie Inc (ABBV) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? AbbVie Inc trades at $253.63 (market cap $449.91B), while State Street SPDR S&P Homebuilders ETF trades at $106.31. The key difference: AbbVie Inc pays a 2.72% dividend while State Street SPDR S&P Homebuilders ETF pays none, and AbbVie Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | XHB | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $121.36 |
52-Week Low | $184.85 | $94.86 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
XHB (SPDR S&P Homebuilders ETF) trades at $111.29, down 1.13% amid mixed housing data. Technical indicators show a bullish bias with strong moving average support, while oscillators remain neutral. Recent news highlights declining new home sales but improving builder sentiment, creating a complex backdrop for the homebuilding sector.
The ETF faces headwinds from higher mortgage rates and construction costs, but potential exists if housing demand recovers. Key risks include interest rate sensitivity and economic uncertainty, while technical support near $108 provides a cushion for near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
